BioSpace News Archive

Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for CIBINQO® (abrocitinib), expanding its indication to include adolescents (12 to <18 years) with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Silver Creek, a biotechnology company headquartered in San Francisco, presented the ARPEGGIO study at the International Stroke Conference in Dallas, Texas.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Alvotech announced the completion of the equity transaction announced on January 23, 2023 with the transfer to the counterparties of a total of 11,834,061 treasury shares previously held by Alvotech’s subsidiary Alvotech Manco ehf.

CureVac N.V. announced the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by CureVac.

Zivo Bioscience, Inc. announced the results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial in broiler chickens.

DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the virtual SBV Securities Global Biopharma Conference taking place February 13 – 16, 2023.

Science 37 Holdings, Inc., the industry-leading Metasite™, announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan.

Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees.